A web-blog (formerly known as Stu's Views and MS News), now published by MS Views and News, a patient advocacy organization. The information on this blog helps to Empower those affected by Multiple Sclerosis globally, with education, information, news and community resources.
~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Friday, April 15, 2016
Natalizumab (Tysabri) Targets Molecule Crucial for Type of B-Cell to Accumulate in the Brain
Mice with experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), were found to have milder symptoms if the target of natalizumab (Tysabri) — VLA4 — was absent on B-cells, preventing regulatory cells that might control immune processes from entering the brain.
B-cells are increasingly thought to play a role in autoimmune processes in the brain. Earlier studies have also shown that Bregs, a type of B-cell with regulatory properties, might be involved in suppressing EAE.
VLA4 is a molecule expressed on the surfaces of B-cells and the target of natalizumab. The expression of the molecule has been shown to mediate important steps in the autoimmune process: when VLA4 is blocked, fewer B-cells accumulate in the brain during EAE, suggesting that natalizumab works in RRMS in part by blocking B-cell accumulation.
B-cell actions, however, are complex, being composed of both immune mediating and immune controlling cells.
Researchers at the University of California, San Francisco, explored if VLA4 was also an important factor in allowing Bregs to accumulate in the brain, speculating that the lack of Bregs in mice might explain their more severe EAE symptoms.
Their findings, presented in the journal Neuroimmunology and Neuroinflammation, showed that in mice lacking VLA4, EAE was less severe than in control mice when the researchers used the B-cell dependent method. In contrast, animals got sicker when EAE was induced by the B-cell independent method.
In mice lacking the natalizumab target having B-cell independent EAE, researchers noted that fewer B-cells had accumulated in the central nervous system. Particularly, the team found that virtually no Bregs had entered the brains of the mice with more severe EAE.